Natera Q3 2026 net loss narrows 32% year over year to $59.91 million
NTRA•Natera’s third-quarter net loss narrowed 32% year over year to $59.91 million, while revenue rose 34% to $794 million. The company raised its 2026 revenue guidance to $3.01 billion–$3.04 billion and expects positive cash flow.
1. Revenue and guidance
Natera reported third-quarter 2026 revenue of $794 million, up 34% year over year, driven by higher volumes and improved average selling prices. Its net loss narrowed 32% to $59.91 million. Oncology tests processed increased 61% to approximately 339,500. Natera raised its 2026 revenue guidance to $3.01 billion–$3.04 billion and expects positive cash flow.
